Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Ireland

Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every 2 weeks) is a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) that may improve treatment adherence by reducing the frequency of administration. The pivotal ADVANCE trial showed benefits of PEG-IFN versus placebo on relapses and disability progression, but its long-term clinical and economic consequences versus other DMTs are still unknown. This analysis assessed the cost-effectiveness of PEG-IFN versus other self-injectable DMTs (Interferon beta-1a 22mcg and 44mcg three times/week, and 30mcg once/week; interferon beta-1b 250mcg every other day; and glatiramer acetate 20mg once/day) from the Health Services Executive perspective in Ireland.

Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: L Hernandez, S Guo, H Toro-Diaz, S Carroll, SF Syed Farooq Source Type: research